Difference between revisions of "Team:UCopenhagen"
| Line 157: | Line 157: | ||
<div class="container text-center content-section sponsor-section"> | <div class="container text-center content-section sponsor-section"> | ||
<div class="row"> | <div class="row"> | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
</div> | </div> | ||
Revision as of 15:34, 20 September 2017
<!DOCTYPE HTML>
Incell: a platform for synthetic endosymbiosis
Incell is a new synthetic biology platform with near future applications in research, industry and services. We are rewriting nature’s code for endosymbiosis and transforming an evolutionary phenomenon into a technology compatible with standard biological parts.
Our vision is to produce synthetic host–endosymbiont systems. We set out with a trinity of experiments intrinsic to the synthetic reconstruction of endosymbiosis. First, creating and sustaining dependence between a host and its endosymbionts by fulfilling the amino acid requirement of an auxotrophic host. Next, to build a modular system of cell-penetrating peptides for protein transport of host nuclear encoded proteins into an endosymbiont, recapitulating a crucial feature of the natural process. Finally, regulating the number of endosymbionts within a host using a CRISPR-Cas system for control of replication.
Further ahead we see a safe, customisable, sustainable technology providing biological solutions to present and future challenges in biotechnology, agriculture and medicine.
